SCHEMBL2204540

SCHEMBL2204540

CC(=O)Nc1ccc2nccc(Oc3ccc(Nc4nnc(-c5ccccc5)c5ccccc45)cc3)c2c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.55
DDR2 Q16832 1/20 0.51
FGFR2 P21802 2/20 0.49
BTK Q06187 2/20 0.48
AURKA O14965 1/20 0.48
AURKB Q96GD4 1/20 0.48
TPX2 Q9ULW0 1/20 0.48
KDR P35968 2/20 0.48
KMT2A Q03164 2/20 0.48
PDGFRA P16234 2/20 0.48
TP53 P04637 1/20 0.48
GAA P10253 1/20 0.48
MEN1 O00255 1/20 0.48
POLB P06746 2/20 0.47
LMNA P02545 1/20 0.47
THRB P10828 2/20 0.46
KDM4E B2RXH2 1/20 0.46
NPSR1 Q6W5P4 1/20 0.46
KIT P10721 1/20 0.46
AXL P30530 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2211767 0.87 FGFR2 (0.58) MAPTDDR2FGFR2AURKAAURKB
SCHEMBL2209074 0.85 FGFR2 (0.50) MAPTFGFR2AURKAAURKBTPX2
SCHEMBL2207029 0.83 FGFR2 (0.72) MAPTFGFR2KDRPDGFRALMNA
SCHEMBL2211183 0.83 FGFR2 (0.48) MAPTFGFR2AURKAAURKBTPX2
SCHEMBL2208900 0.83 FGFR2 (0.63) MAPTFGFR2AURKAAURKBTPX2
SCHEMBL2210933 0.82 RET (0.63) MAPTFGFR2AURKAAURKBKDR
SCHEMBL2210992 0.81 FGFR2 (0.58) MAPTFGFR2AURKAAURKBTPX2
SCHEMBL2210302 0.80 CCNC (0.51) MAPTFGFR2AURKAAURKBTPX2
SCHEMBL2209315 0.80 MAPT (0.54) MAPTFGFR2KDRKMT2APDGFRA
SCHEMBL14047121 0.80 FGFR2 (0.62) MAPTFGFR2AURKAAURKBTPX2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7981891-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2011-07-19 US claimed
US-20100280008-A1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2010-11-04 US claimed
US-20140336182-A1 Aurora Kinase Modulators and Method of Use AMGEN INC (US) 2014-11-13 US disclosed
US-20140336182-A1 Aurora Kinase Modulators and Method of Use AMGEN INC (US) 2014-11-13 US disclosed
US-20140336182-A1 Aurora Kinase Modulators and Method of Use AMGEN INC (US) 2014-11-13 US disclosed
EP-2137177-B1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC (US) 2014-05-07 EP disclosed
EP-2137177-B1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC (US) 2014-05-07 EP disclosed
US-8557816-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2013-10-15 US disclosed
US-8557816-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2013-10-15 US disclosed
US-8557816-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2013-10-15 US disclosed
US-20120122847-A1 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2012-05-17 US disclosed
US-7776857-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2010-08-17 US disclosed
US-7776857-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2010-08-17 US disclosed
US-7776857-B2 Aurora kinase modulators and method of use AMGEN INC. (US) 2010-08-17 US disclosed
EP-2137177-A2 AURORA KINASE MODULATORS AND METHOD OF USE Amgen, Inc (US) 2009-12-30 EP disclosed
US-20090069297-A1 Aurora kinase modulators and method of use AMGEN INC. (US) 2009-03-12 US disclosed
US-20090069297-A1 Aurora kinase modulators and method of use AMGEN INC. (US) 2009-03-12 US disclosed
US-20090069297-A1 Aurora kinase modulators and method of use AMGEN INC. (US) 2009-03-12 US disclosed
WO-2008124083-A2 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2008-10-16 WO disclosed
WO-2008124083-A2 AURORA KINASE MODULATORS AND METHOD OF USE AMGEN INC. (US) 2008-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140336182-A1 Aurora Kinase Modulators and Method of Use AURKC, AURKA, CDK1 MAPT 1693/4885DDR2 1318/4885FGFR2 334/4885
US-20090069297-A1 Aurora kinase modulators and method of use AURKC, AURKA, CDK1 MAPT 1693/4885DDR2 1318/4885FGFR2 334/4885
US-20100280008-A1 AURORA KINASE MODULATORS AND METHOD OF USE AURKC, AURKA, CDK1 MAPT 1693/4885DDR2 1318/4885FGFR2 334/4885
US-20120122847-A1 AURORA KINASE MODULATORS AND METHOD OF USE AURKC, AURKA, CDK1 MAPT 1693/4885DDR2 1318/4885FGFR2 334/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.